Results 11 to 20 of about 601,308 (135)

Intravitreal gas for symptomatic vitreomacular adhesion: a synthesis of the literature [PDF]

Acta Ophthalmologica, 2017
AbstractSymptomatic vitreomacular adhesion (sVMA) is defined as visual loss secondary to foveal damage from vitreomacular traction (VMT) and includes isolated VMT, impending macular hole (MH), and full‐thickness MH with persisting vitreous attachment.
James E. Neffendorf, Andrew R.H. Simpson, David H.W. Steel, Riti Desai, Dominic A. McHugh, Edward Pringle, Timothy L. Jackson   +6 more
core   +9 more sources

Ocriplasmin for symptomatic vitreomacular adhesion. [PDF]

Cochrane Database Syst Rev, 2017
Symptomatic vitreomacular adhesion (sVMA) is a recognised cause of visual loss and by tradition has been managed by pars plana vitrectomy (PPV). A less invasive alternative to surgery in some people is enzymatic vitreolysis, using an intravitreal injection of ocriplasmin.To assess the efficacy and safety of ocriplasmin compared to no treatment, sham or
Neffendorf JE, Kirthi V, Pringle E, Jackson TL.   +3 more
europepmc   +8 more sources

Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential. [PDF]

Core Evid, 2014
Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion. The advent of optical coherent tomography (OCT) has demonstrated the anatomic features of persistent vitreomacular attachment (VMA) more definitively, including in many asymptomatic or ...
Song SJ, Smiddy WE.
europepmc   +7 more sources

Cost–effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US [PDF]

Journal of Comparative Effectiveness Research, 2020
Aim: Evaluate the cost–effectiveness of ocriplasmin in symptomatic vitreomacular adhesion (VMA) with or without full-thickness macular hole ≤400 μm versus standard of care. Methods: A state-transition model simulated a cohort through disease health states; assignment of utilities to health states ...
Khanani, Arshad M, Dugel, Pravin U, Haller, Julia A, Wagner, Alan L, Lescrauwaet, Benedicte, Schmidt, Ralph, Bennison, Craig   +6 more
core   +4 more sources

ASSOCIATION BETWEEN ANATOMICAL RESOLUTION AND FUNCTIONAL OUTCOMES IN THE MIVI-TRUST STUDIES USING OCRIPLASMIN TO TREAT SYMPTOMATIC VITREOMACULAR ADHESION/VITREOMACULAR TRACTION, INCLUDING WHEN ASSOCIATED WITH MACULAR HOLE

Retina, 2015
To evaluate visual function in patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction including when associated with macular hole after ocriplasmin treatment, and the association between resolution of the underlying condition and improvement in visual function.Six hundred and fifty-two patients from 2 Phase 3 trials received a ...
Arnd, Gandorfer, Matthew S, Benz, Julia A, Haller, Peter, Stalmans, Stephen J, Pakola, Aniz, Girach, Anselm, Kampik, Cynthia A, Toth, Glenn J, Jaffe   +8 more
openaire   +3 more sources

PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY. [PDF]

Retina, 2020
Purpose: To evaluate patient-reported visual function after ocriplasmin through the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) in patients with symptomatic vitreomacular adhesion/vitreomacular traction including macular hole.
Mein C, Dugel PU, Feiner L, Drenser K, Miller D, Benz M, Meunier E, Moro L, Fineman MS.   +8 more
europepmc   +4 more sources

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA [PDF]

Journal of Comparative Effectiveness Research, 2018
Background: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea ® ). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection ...
Tiffany M, Yu, Pravin U, Dugel, Julia A, Haller, Peter K, Kaiser, Renée Jg, Arnold   +4 more
openaire   +2 more sources

Incidence of unplanned visits after cataract surgery in two large cohorts with different anti‐inflammatory treatment protocols

Acta Ophthalmologica, Volume 101, Issue 3, Page 310-318, May 2023., 2023
Abstract Purpose To compare incidences and reasons for unplanned extra visits after phacoemulsification surgery in two unselected clinical populations with different postoperative treatment protocols. Design Retrospective cohort study. Methods We reviewed medical records of 1000 patients that underwent cataract surgery at two adjacent clinics in Sweden.
Jan Gärdin, Björn Johansson
wiley   +1 more source

Evaluation of the Efficacy of Pneumatic Vitreolysis Treatment for Symptomatic Vitreomacular Traction Syndrome

, 2022
Purpose: To evaluate the posterior vitreous release rates after a single injection of expansile gas in patients with focal vitreomacular traction (VMT) syndrome.
Kupeli, Ayca, Garip, Ruveyde, Ozal, Sadık, Ozal, Ece   +3 more
core   +1 more source

[Vitreomacular Traction Syndrome (VMTS)].

, 2013
In vitreomacular traction syndrome (VMTS) an anomalous posterior vitreous detachment (APVD) with persistant symptomatic vitreoretinal adhesion is seen. The adhesion leads to a thickened macula, to macular oedema and a reduction of BCVA.
Maier, M M;Feucht, N;Burzer, S;Lohmann, C P
core   +1 more source